Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Prexigebersen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Prexigebersen overview
Prexigebersen (BP-1001) is under development for the treatment of inflammatory breast cancer (IBC), acute myeloid leukemia, primary peritoneal, fallopian tube, endometrial tumor including serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, mucinous adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma, mesonephric carcinoma and obesity. It is administered intravenously. The therapeutic candidate is an antisense oligonucleotide that constitutes liposomal antisense Grb-2 (growth factor-bound protein-2). It is developed based on DNAbilize liposomal antisense technology, which uses positively charged lipids to form complexes between the lipids and the molecules of interest.
Prexigebersen was under development for myelodysplastic syndrome, systemic lupus erythematosus, chronic myelocytic leukemia, acute lymphocytic leukemia and relapsed and refractory acute myeloid leukemia.
Bio-Path overview
Bio-Path is a clinical-stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML), gynecological cancer. The company provides product pipelines such as prexigebersen and BP1002 (Liposomal Bcl2). Its prexigebersen is developed for the treatment of AML and solid tumors. Bio-Path’s BP1002 (Liposomal Bcl2) is used for the treatment of lymphoma, leukemia, colon, prostate and breast cancers, among others. The company’s proprietary liposomal delivery and antisense technology platform DNAbilize, is used to systemically distribute nucleic acid drugs throughout the human body with an intravenous transfusion. Bio-Path is headquartered in Bellaire, Texas, the US.
For a complete picture of Prexigebersen’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
